A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing’s sarcoma

Many sarcomas and leukemias carry nonrandom chromosomal translocations encoding tumor-specific mutant fusion transcription factors that are essential to their molecular pathogenesis. Ewing’s sarcoma family tumors (ESFTs) contain a characteristic t(11;22) translocation leading to expression of the oncogenic fusion protein EWS-FLI1. EWS-FLI1 is a disordered protein that precludes standard structure-based small-molecule inhibitor design. EWS-FLI1 binding to RNA helicase A (RHA) is important for its oncogenic function. We therefore used surface plasmon resonance screening to identify compounds that bind EWS-FLI1 and might block its interaction with RHA. YK-4-279, a derivative of the lead compound from the screen, blocks RHA binding to EWS-FLI1, induces apoptosis in ESFT cells and reduces the growth of ESFT orthotopic xenografts. These findings provide proof of principle that inhibiting the interaction of mutant cancer-specific transcription factors with the normal cellular binding partners required for their oncogenic activity provides a promising strategy for the development of uniquely effective, tumor-specific anticancer agents.

[1]  Stephen C. Haroldsen,et al.  Microsatellites as EWS/FLI response elements in Ewing's sarcoma , 2008, Proceedings of the National Academy of Sciences.

[2]  O. Delattre,et al.  Alteration of cyclin D1 transcript elongation by a mutated transcription factor up-regulates the oncogenic D1b splice isoform in cancer , 2008, Proceedings of the National Academy of Sciences.

[3]  Amanda C. Winters,et al.  The AF4-mimetic peptide, PFWT, induces necrotic cell death in MV4-11 leukemia cells. , 2008, Leukemia research.

[4]  P. Leeson,et al.  The influence of drug-like concepts on decision-making in medicinal chemistry , 2007, Nature Reviews Drug Discovery.

[5]  Tariq M Rana,et al.  RNA helicase A interacts with RISC in human cells and functions in RISC loading. , 2007, Molecular cell.

[6]  O. Delattre,et al.  Mesenchymal stem cell features of Ewing tumors. , 2007, Cancer cell.

[7]  B. Johansson,et al.  The impact of translocations and gene fusions on cancer causation , 2007, Nature Reviews Cancer.

[8]  Christopher J. Oldfield,et al.  Functional anthology of intrinsic disorder. 1. Biological processes and functions of proteins with long disordered regions. , 2007, Journal of proteome research.

[9]  Vladimir N Uversky,et al.  Multiple aromatic side chains within a disordered structure are critical for transcription and transforming activity of EWS family oncoproteins , 2007, Proceedings of the National Academy of Sciences.

[10]  Marc S. Cortese,et al.  Rational drug design via intrinsically disordered protein. , 2006, Trends in biotechnology.

[11]  O. Silvennoinen,et al.  Characterization of RNA helicase A as component of STAT6-dependent enhanceosome , 2006, Nucleic acids research.

[12]  Vladimir N Uversky,et al.  Local Flexibility in Molecular Function Paradigm* , 2006, Molecular & Cellular Proteomics.

[13]  J. Parvin,et al.  Oncoprotein EWS-FLI1 activity is enhanced by RNA helicase A. , 2006, Cancer research.

[14]  Cheryl Bolinger,et al.  RNA helicase A is necessary for translation of selected messenger RNAs , 2006, Nature Structural &Molecular Biology.

[15]  J. Toretsky,et al.  Activation of the canonical Wnt pathway during genital keratinocyte transformation: a model for cervical cancer progression. , 2005, Cancer research.

[16]  G. Colombo,et al.  Rational design of shepherdin, a novel anticancer agent. , 2005, Cancer cell.

[17]  C. Antonescu,et al.  Midline carcinoma of children and young adults with NUT rearrangement. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  J. Toretsky,et al.  Recombinant EWS-FLI1 oncoprotein activates transcription. , 2004, Biochemistry.

[19]  T. Okamoto,et al.  RNA helicase A interacts with nuclear factor kappaB p65 and functions as a transcriptional coactivator. , 2004, European journal of biochemistry.

[20]  A. Safa,et al.  RNA Helicase A in the MEF1 Transcription Factor Complex Up-regulates the MDR1 Gene in Multidrug-resistant Cancer Cells* , 2004, Journal of Biological Chemistry.

[21]  L. Roudaia,et al.  Penetratin and related cell-penetrating cationic peptides can translocate across lipid bilayers in the presence of a transbilayer potential. , 2003, Biochemistry.

[22]  P. Meltzer,et al.  Mechanisms of sarcoma development , 2003, Nature Reviews Cancer.

[23]  H. Kovar,et al.  Potentials for RNAi in sarcoma research and therapy: Ewing's sarcoma as a model. , 2003, Seminars in cancer biology.

[24]  S. Donaldson,et al.  Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. , 2003, The New England journal of medicine.

[25]  L. Cantley,et al.  An integrated vector system for cellular studies of phage display-derived peptides. , 2002, Analytical biochemistry.

[26]  S. Baker,et al.  EWS/FLI Alters 5′-Splice Site Selection* , 2001, The Journal of Biological Chemistry.

[27]  Fengzhi Li,et al.  Control of apoptosis and mitotic spindle checkpoint by survivin , 1998, Nature.

[28]  K. Manova,et al.  RNA helicase A is essential for normal gastrulation. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[29]  Erica A Golemis,et al.  Oncogenic EWS-Fli1 interacts with hsRPB7, a subunit of human RNA polymerase II , 1998, Oncogene.

[30]  J. Parvin,et al.  BRCA1 protein is linked to the RNA polymerase II holoenzyme complex via RNA helicase A , 1998, Nature Genetics.

[31]  M. Carroll,et al.  CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. , 1997, Blood.

[32]  Jeffrey D. Parvin,et al.  RNA Helicase A Mediates Association of CBP with RNA Polymerase II , 1997, Cell.

[33]  K. Tanaka,et al.  EWS-Fli1 antisense oligodeoxynucleotide inhibits proliferation of human Ewing's sarcoma and primitive neuroectodermal tumor cells. , 1997, The Journal of clinical investigation.

[34]  T. Triche,et al.  The Ewing family of tumors--a subgroup of small-round-cell tumors defined by specific chimeric transcripts. , 1994, The New England journal of medicine.

[35]  B. Neel,et al.  Use of a general purpose mammalian expression vector for studying intracellular protein targeting: identification of critical residues in the nuclear lamin A/C nuclear localization signal. , 1993, Journal of cell science.

[36]  G. Thomas,et al.  Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours , 1992, Nature.

[37]  中谷 文彦.  Identification of p21WAF1/CIP1 as a direct target of EWS-Fli1 oncogenic fusion protein , 2004 .

[38]  C. Bloomfield,et al.  Expression analyses identify MLL as a prominent target of 11q23 amplification and support an etiologic role for MLL gain of function in myeloid malignancies. , 2004, Blood.